Synergistic effects of ivabradine and metformin in the treatment of concomitant chronic heart failure and diabetes mellitus by regulating the activity of the H19/miR-423-5p/HCN4 axis

Type

Research paper

Keywords

diabetes mellitus, metformin, chronic heart failure, ivabradine, H19, miR-423-5p, HCN4

Abstract

Introduction

In this study, the molecular mechanisms underlying the therapeutic effect of metformin (MET) and ivabradine (IBD) in the treatment of concomitant chronic heart failure (CHF) and diabetes mellitus (DM) were investigated.

Material and methods

Basic and cardiac indexes were measured to study the therapeutic effect of MET and IBD. Real-time PCR, IHC assays, in-silicon analysis, luciferase assays, real-time PCR and Western blot assays were conducted to clarify the molecular mechanisms underlying the interaction between MET and IBD.

Results

MET administration restored the normal values of general/cardiac indexes in CHF rats. The abnormal values of echocardiographic indexes in CHF rats with STZ-induced DM were all corrected by a certain degree after the MET administration. Moreover, the injection of STZ up-regulated the expression of plasma NE/BNP-45, while the IBD administration reduced the levels of NE/BNP-45 in CHF rats. Furthermore, the administration of MET also reduced the NE level in CHF rats, indicating that both MET and IBD can exert a therapeutic effect on CHF rats. Additionally, in-silicon analysis and luciferase assays verified the role of H19 and HCN4 as target genes of miR-423-5p. In fact, the transfection of MET or H19 siRNA1/2 into HL-1 and H9C2 cells down-regulated the levels of H19 and HCN4 while increasing the level of miR-423-5p.

Conclusions

MET reduces H19 expression via inducing methylation of its promoter, and the inhibited H19 expression suppresses HCN4 expression by up-regulating miR-423-5p expression. As a result, the suppressed expression of HCN4 reduces heart rate and exhibits a therapeutic effect in the treatment of concomitant CHF and DM.

Synergistic effects of ivabradine and metformin in the treatment of concomitant chronic heart failure and diabetes mellitus by regulating the activity of the H19/miR-423-5p/HCN4 axis

Fang Zhang ^{1*}, Weijun Jiang ¹, Yating Liu ¹, Liu Li ¹, Rui Wang ², Yang Li ³

1. Ultrasound Diagnosis Department II, The First Hospital of Qinhuangdao

2. Endocrinology Department I, The First Hospital of Qinhuangdao

3. Research Department, The First Hospital of Qinhuangdao

Correspondence to: Fang Zhang, Ultrasound Diagnosis Department II, The first hospital of Qinhuangdao, No.258 Wenhua Road, Haigang District, Qinhuangdao 066000, Hebei Province, China; Email: heartsung@yeah.net

Abstract

Aims: As a type of frequently diagnosed heart disease, chronic heart failure (CHF) is featured by a high incidence of mortality and morbidity. Previous studies have shown that ivabradine (IBD) could exert a therapeutic effect in CHF patients, and that the presence of diabetes mellitus (DM) may reduce the therapeutic effect of IBD in the treatment of CHF. Moreover, metformin (MET) was shown to induce the methylation of H19, which may enable MET to function as a sensitizer of IBD in the treatment of CHF, especially in those with DM. Therefore, in this study, we investigated the molecular mechanisms underlying the therapeutic effect of MET and IBD in the treatment of CHF and DM. **Methods:** SD rat models groups were established as a CHF + streptozotocin (STZ) + MET group, a CHF + IBD group, a CHF + STZ + IBD group, and a CH + STZ + IBD + MET group, with 20 rats in each group. Basic and cardiac indexes were measured to study the therapeutic effect of MET and IBD via transthoracic echocardiography. Real-time PCR, ELISA, immunohistochemistry (IHC) assays and Western blot assay were conducted to observe the expressions of H19, miR-423-5p, NE, BNP-45 and HCN4. In-silicon analysis and luciferase assays were further conducted to establish the signaling pathway and clarify the molecular mechanisms underlying the interaction between MET and IBD. **Results:** MET administration restored the normal values of general/cardiac

indexes in CHF rats. The abnormal values of echocardiographic indexes in CHF rats with STZ-induced DM were all corrected by a certain degree after the MET administration. Moreover, the injection of STZ up-regulated the expression of plasma NE/BNP-45, while the IBD administration reduced the levels of NE/BNP-45 in CHF rats. Furthermore, the administration of MET also reduced the NE level in CHF rats, indicating that both MET and IBD can exert a therapeutic effect on CHF rats. Additionally, in-silicon analysis and luciferase assays verified the role of H19 and HCN4 as target genes of miR-423-5p. In fact, the transfection of MET or H19 siRNA1/2 into HL-1 and H9C2 cells down-regulated the levels of H19 and HCN4 while increasing the level of miR-423-5p. **Conclusions:** MET reduces H19 expression via inducing methylation of its promoter, and the inhibited H19 expression suppresses HCN4 expression by up-regulating miR-423-5p expression. As a result, the suppressed expression of HCN4 reduces heart rate and exhibits a therapeutic effect in the treatment of concomitant CHF and DM.

Running title: MET improves therapeutic effect of ivabradine

Key word: chronic heart failure, diabetes mellitus, ivabradine, metformin, H19, miR-423-5p, HCN4

Introduction

As a type of frequently diagnosed heart disease, chronic heart failure (CHF) is featured by a high incidence of mortality and morbidity [1]. Currently, about 2% of adults in Western countries suffer from CHF, while the prevalence of CHF rises above 10% in patients older than 70 years [2]. Although significant progress has been made in the treatment of CHF along with a decreased period of hospitalization required for many CHF patients, an European Society of Cardiology Heart Failure (ESC-HF) pilot study conducted in Europe showed that the 12-month mortality among hospitalized CHF patients was still as high as about 20% [3]. In addition, the prevalence of CHF increases over growing age and the presence of chronic diseases, including type 2 diabetes mellitus (T2DM), obesity, and hypertension [4]. Moreover, due to the current epidemic of obesity and diabetes, the incidence of CHF also increases gradually in recent years [5].

Hyperpolarization-activated cyclic nucleotide-gated (HCN) ion channels, coded by HCN 1-4 genes, are responsible for the generation of hyperpolarization-activated current. Contain four isotypes, the HCN family can modulate synaptic integration and intrinsic neuronal excitability [6, 7]. In addition, the presence of cyclic Adenosine monophosphate (cAMP) can induce the activation of HCN channels [8]. Therefore, the activation of HCN channels is increased by cAMP-coupled receptors. In particular, among the four members of the HCN family, HCN4 shows the highest affinity for cAMP [9]. Moreover, gene microarrays have implicated the upregulation of HCN4 expression in the impairment of human ventricular functions [10]. For example, it was suggested that the upregulation of HCN4 expression in the atrial tissues contributes to the elevated level of atrial ectopic-beat upon atrial dilation. Therefore, potential inhibitors of HCN channels, including ivabradine (IBD) and zatebridine, may be used in the clinical treatment of CHF-induced atrial tachyarrhythmias [11].

As a specific inhibitor of HCN channels located in cardiac pacemaker cells [12], IBD can lead to a reduced level of heart rate during both exercise and resting states, without exerting any effect on blood pressure and cardiac contractility [13]. In fact, IBD was shown to exert a therapeutic effect in CHF patients by affecting the remodeling of left ventricle [14, 15]. Moreover, it was revealed that IBD enhances cardiac functions by restoring the uptake-1 of norepinephrine (NE) via specific signaling pathways, thus decreasing the elevated levels of BNP-45 and NE in CHF [16]. Other findings suggested that the activity of IBD is inhibited in diabetic hyperglycemia, potentially caused by the impaired uptake-1 of NE [16].

Multiple classes of non-coding RNAs, such as long non-coding RNAs (lncRNAs) and microRNAs (miRNAs), have been shown to play essential roles in the regulation of gene expression [17]. Furthermore, lncRNAs can also regulate mRNA expression by inducing its translation or degradation [17]. For example, the hypermethylation of H19 promoter was found to reduce the level of H19 in both mouse and human [18, 19]. Moreover, it was shown that metformin (MET), a compound with both anti-cancer and anti-diabetic properties, reduces the expression of H19 by inducing the methylation of H19 [20].

Previous findings showed that the presence of diabetes mellitus (DM) may reduce the therapeutic effect of IBD in the treatment of CHF [16]. Meanwhile, it has also been shown that MET may reduce the expression of H19 by enhancing the methylation status of H19 promoter, which subsequently promotes the expression of miR-423-5p and suppresses the expression of HCN4, a target of miR-423-5p [17]. Therefore, we hypothesized that MET may function as a sensitizer of IBD in the treatment of CHF, especially in those with DM.

Therefore, with respect to the fact that MET could reduce the expression of H19 and H19 could influence the expression of miR-423-5p, we assumed that MET could reduce the expression of HCN4 via modulating the H19/miR-423-5p/HCN4 signaling in DM. Moreover, as the effect of IBD was suppressed by DM in the treatment of CHF, we therefore focused the study aim upon the possible synergistic effects of IBD and MET in the treatment of concomitant CHF and DM.

Materials and Methods

Animal and treatment

A total of 180 healthy male Sprague Dawley (SD) rats with an average body weight of about 200 g were purchased from the animal center of our institute and used in this study. All rats were kept in an SPF grade animal facility with a 12-h light/dark cycle, under a specific temperature (18~22°C), relative humidity (40~70%), and a noise level of < 50 dB, and were given ad libitum access to water and food. The rats were randomly assigned into 9 groups, i.e., a control group (sham-operated healthy SD rats), a streptozotocin (STZ) group, a STZ + MET group, a CHF group, a CHF + STZ group, a CHF + STZ + MET group, a CHF + IBD group, a CHF + STZ + IBD group, and a CHF + STZ + IBD + MET group, with 20 rats in each group. During the experiment, the rats in the groups involving MET treatment were given 250 mg/kg of MET via oral administration from day 1 to day 18 of the experiment. In the control group, the rats were given water to replace MET. The rats in the groups involving IBD treatment were given 10 mg/kg of IBD (Sigma-Aldrich, St. Louis, MO) via daily i.p. injection after the establishment of the CHF model

was completed. The rats in other groups were treated according to the procedures described below. The experimental protocol and animal use plan in this study were approved by the Animal Ethics Committee of our institute, while all experiments were carried out in strict accordance with National Institutes of Health (NIH) guidelines.

Induction of Diabetes

STZ (Sigma-Aldrich, St. Louis, MO) was dissolved in saline and given to rats in a single dose of 70 mg/kg via i.p. injection to induce diabetes. The presence of diabetes was then confirmed 4 weeks later by the measurement of blood glucose level. A blood glucose level of >350 mg/dl was considered as the criterion for the successful modeling of diabetic rats.

Establishment of CHF

The CHF rats were generated via coronary artery ligation. In brief, the rats were anesthetized through the inhalation of a mixture of oxygen containing 5% of isoflurane. Subsequently, the rats underwent left thoracotomy performed between the 4th and the 5th ribs. After the left ventricular wall was carefully exposed, myocardial infarction was induced by permanently ligating the left anterior descending artery using a polypropylene suture. In the next step, the lungs of the rats were hyper-inflated via a positive end-expiratory pressure. Subsequently, the chest opening in the rats was sutured and the survival of rats was monitored for 24 h.

The size of myocardial infarction and left ventricular function

At about 7 weeks after the model establishment, the rats were anesthetized to measure their dimensions of left ventricle and heart rate using transthoracic echocardiography. A phased array transducer was used to carry out the measurements according to the manufacturer's instructions. In addition, at the end of each measurement, a catheter was placed in the right carotid artery of the rats to determine the arterial blood pressure and the left ventricular end-diastolic pressure, the two parameters later used to evaluate the cardiac functions of the rats in different groups. In terms of the size of

myocardial infarction, all rats were euthanized at the end of experiment and the heart of each rat was removed to estimate the size of myocardial infarction according to the method described in the literature [28-31].

Measurements of NE and BNP-45 by ELISA

The expression of NE and BNP-45 in the rats of different groups was measured using aortic blood samples, while the uptake-1 of NE was measured using the myocardium tissue samples taken from healthy tissues adjacent to the infarcted tissues of stellate ganglion collected from each rat. In brief, after blood samples were collected from aorta, they were immediately transferred into EDTA-coated blood sampling tubes. Subsequently, the levels of NE and BNP-45 in blood samples were measured using corresponding ELISA kits (RapidBio Systems, Minneapolis, MN) following the instructions of the manufacturer. During the measurement, the antigens were diluted at a ratio of 1 : 20, and each well of the ELISA plate was added with 100 μ L of standard diluent and then incubated at 4°C overnight. On the next day, diluted samples and HRP-labeled substrate were added into the ELISA plate and incubated in the dark at 37°C for 20 min. When an obvious color change occurred in the positive control, or when a slight color change occurred in the negative control, the reaction in the wells was terminated by the addition of 50 μ L of a terminating reagent. Within 20 min, the optical density (OD) value of each well was measured at a wavelength of 450 nm on a microplate reader (SpectraMax M5, Molecular Devices, San Jose, CA). The uptake of NE in stellate ganglion tissue samples was measured in a similar way after the tissue samples were homogenized into a homogenate by a blender.

RNA isolation and real-time PCR

Total RNA was extracted from tissue and cell samples using a TRIZOL kit (Invitrogen, Carlsbad, CA) in strict accordance with the kit instructions. RNA concentration was determined using a spectrometer. Primers for H19, miR-423-5p, and HCN4 mRNA were synthesized by Takara (Tokyo, Japan). The reverse transcription was performed using a reverse transcription kit (Thermo Fisher Scientific, Waltham, MA) with reference to the

manufacturer's instructions. The reaction conditions of reverse transcription were as follows: 50 min of reverse transcription at 42°C followed by 5 s of reverse transcriptase inactivation at 85°C. The obtained cDNA was then diluted to 50 ng/μL for subsequent real-time PCR. The amplification system of qPCR contained 25 μL. The real-time PCR was performed on an ABI 7900 real-time PCR instrument (ABI, Foster City, CA). The real-time PCR conditions were as follows: pre-denaturation at 95°C for 4 min, followed by 30 cycles of denaturation at 95°C for 30 s, annealing at 57°C for 30 s and extension at 72°C for 30 s. A total of 2 μg cDNA was used as the qPCR template for each target gene, while β-actin was used as the internal reference. The $2^{-\Delta\Delta Ct}$ method was used to calculate the relative expression of H19, miR-423-5p, and HCN4 mRNA. And the primer pairs used were: H19-F: 5'-TGCTGCACTTTACAACCACTG-3'; H19-R: 5'-ATGGTGTCTTTGATGTTGGGC-3'; miR-423-5p-F: 5'-GGCTGAGGGGCAGAGAG-3'; miR-423-5p-R: 5'-GTGCAGGGTCCGAGGT-3'; HCN4-F: 5'-CCCAAGAACCTTCCCGAGTG-3'; HCN4-R: 5'-GATGTCTTCCGAGGCAGAGTGA-3'.

Cell culture and transfection

HL-1 and H9C2 cells were purchased from the Cell Bank of the Chinese Academy of Sciences and cultured at 37°C and 5% CO₂ in a Dulbecco's modified eagle medium (DMEM) (Gibco, Carlsbad, CA) containing 10% fetal bovine serum (Gibco, Carlsbad, CA), 100 μg/mL penicillin and 100 μg/mL streptomycin (Invitrogen, Carlsbad, CA). The cells were harvested during logarithmic growth by trypsinization and then sub-cultured 1-2 times a week. For MET treatment, the cells were incubated with 0.5 μM or 1 μM of MET for 48 h before the cells were harvested for analysis. In addition, to test the effect of H19 on the expression of miR-423-5p and HCN4, HL-1 and H9C2 cells were transfected with H19 siRNA1 or siRNA2 using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) in accordance with the instructions provided by the manufacturer. The cells were harvested at 48 h post transfection and used for subsequent experiments.

Vector construction, mutagenesis and luciferase assay

To clarify the regulatory relationship between miR-423-5p and H19/HCN4 mRNA, an online bioinformatics tool was used to locate potential binding sites of miR-423-5p in H19 and the 3' UTR of HCN4 mRNA, respectively. Subsequently, the full-length of H19 as well as the 3' UTR of HCN4 mRNA containing the binding site of miR-423-5p was amplified by PCR and cloned into a pcDNA3.1 vector (Promega, Madison, WI), respectively. In addition, site-directed mutagenesis was carried out in the miR-423-5p binding sites of H19 and the 3' UTR of HCN4 mRNA, respectively, and the mutant sequences of H19 and the 3' UTR of HCN4 mRNA were respectively inserted into pcDNA3.1 vectors to create the mutant plasmids of H19 and HCN4 mRNA. In the next step, HL-1 and H9C2 cells were co-transfected with miR-423-5p and mutant/wild type of H19 or HCN4 mRNA. After 48 h of transfection, the cells were collected and the luciferase activity of transfected cells was measured using a Dual-luciferase reporter gene assay system (Promega, Madison, WI), in which both the firefly luciferase activity of target genes and the Renilla luciferase activity of the internal control were measured. The expression of H19 or HCN4 mRNA was then calculated in terms of their relative luciferase activity.

Western blot analysis

Total protein was extracted from tissue and cell samples, resolved by 10% SDS-PAGE, and transferred onto a polyvinylidene fluoride (PVDF) membrane. The membrane was blocked with 5% bovine serum albumin at room temperature for 1 h, incubated with anti-HCN4 primary antibodies (ab32675, Abcam, Cambridge, MA) at 4°C overnight, incubated with HRP-labeled IgG secondary antibodies (ab6721, Abcam, Cambridge, MA) at room temperature for 1 h, colorized by an ECL reagent, and analyzed by Image J software to calculate the protein expression of HCN4, which was normalized to the expression of β -actin.

Immunohistochemistry

The expression of HCN4 in tissue samples was measured using conventional immunohistochemistry assays. IHC results were processed with ImageJ software.

Statistical analysis

All statistical analyses were conducted using SPSS 18 software (IBM, Chicago, IL). In addition, the comparisons between two groups were carried out by *t* test, while the comparisons among multiple groups were carried out by one-way analysis of variance (ANOVA), following by Scheffe's test as the post hoc test. Each experiment was biologically repeated in triplicate. All results were original and strictly verified for their correctness. The measurement data were expressed as mean $\pm$ standard deviation. A *p* value of < 0.05 was considered statistically significant.

Results

General/cardiac measurements of experimental rats

Fig.1 illustrated the changes of general/cardiac characteristics as well as echocardiographic values in the rats from the STZ, STZ+ MET, CHF, CHF+STZ, CHF+STZ+ MET, CHF+IBD, CHF+STZ+IBD, and CHF+STZ+IBD+ MET groups (20 rats/group) in comparison with the values in the control group.

The concentrations of blood glucose (Fig.1A) did not differ significantly after the induction of CHF, while evident increases in blood glucose concentrations were observed in the STZ, CHF+STZ, and CHF+STZ+IBD groups. Therefore, the body weight (Fig.1B) of the rats exposed to STZ was slightly decreased. Meanwhile, body indexes, including heart weight (Fig.1C), the ratio of heart weight/body weight (Fig.1D), and infarct size (Fig.1E), were all increased in CHF rats regardless of STZ exposure. Interestingly, the administration of MET in STZ rats, CHF+STZ rats and CHF+STZ+IBD rats restored the general/cardiac characteristics of these rats to a level similar to that in the control rats, CHF rats and CHF+IBD rats. In addition, the value of mean arterial pressure (Fig.1F) was not significantly altered among different groups, while a decreased heart rate (Fig.1G) was only observed in CHF+IBD rats.

Echocardiographic measurements in experimental rats

Subsequently, echocardiographic measurements were carried out to determine the values of left ventricular end-diastolic dimension (LVDD), left ventricular end-systolic dimension (LVSD), left ventricular fractional shortening (LVFS), left ventricular end-diastolic pressure (LVEDP), strain rate (SR), cardiac output (CO) and cardiac index (CI) in the rats from different groups. As exhibited by the results, the values of LVDD (Fig.1H), LVSD (Fig.1I) and LVEDP (Fig.1K) were all increased in CHF rats compared with those in the control group, while the administration of IBD decreased the values of these indexes to a certain extent. In addition, all rats exposed to STZ showed higher index values compared with the rats not exposed to STZ. On the contrary, the value of LVFS (Fig.1J), SR (Fig.1N), CO (Fig.1O) and CI (Fig.1P) were decreased in CHF rats compared with that in the control group, while the administration of IBD evidently increased the according values in CHF rats. Similarly, the rats exposed to STZ showed a lower value of LVFS, SR, CO and CI compared with the rats not exposed to STZ. Finally, the administration of MET in the rats exposed to STZ corrected the abnormal values of LVDD, LVSD, LVFS, LVEDP, SR, CO and CI to a certain extent.

Levels of NE and BNP-45 in experimental rats

As shown in Fig.1L and compared with that in the control rats, the level of plasma NE was evidently elevated in CHF rats with or without STZ exposure, while the rats exposed to STZ showed a higher level of plasma NE than the rats not exposed to STZ. In addition, the CHF rats treated by IBD showed a lower level of NE than the CHF rats not treated by IBD, but a higher level of NE than control rats. Additionally, the administration of MET also reduced the level of NE in the rats exposed to STZ. Similarly, the level of BNP-45 (Fig.1M) showed a similar trend as that of NE. Therefore, the changes in general/cardiac and echocardiographic indexes as well as the changes in NE and BNP-45 expression indicated that MET exerted a synergistic and therapeutic effect with IBD during CHF treatment.

Levels of H19, miR-423-5p and HCN4 in experimental rats

Levels of H19, miR-423-5p, and HCN4 in the rats from different groups were measured. An evident decrease in the expression of H19 (Fig.2A) as well as in the mRNA (Fig.2C) and protein (Fig.2D) expression of HCN, along with a significantly increased level of miR-423-5p (Fig.2B), was observed in the STZ+ MET, CHF+STZ+ MET, and CHF+STZ+IBD+ MET groups. Moreover, when observing the methylation status of H19, MET was found to evidently promote H19 methylation compared with other groups (Fig.2E). In addition, IHC assays observed a reduced level of HCN protein (Fig.3) in the myocardial tissues collected from the rats in the STZ+ MET, CHF+STZ+ MET, and CHF+STZ+IBD+ MET groups. Therefore, it can be assumed that the positive effects of MET on the activity of IBD during CHF treatment might be associated with the expression of H19, miR-423-5p and HCN4.

Association among H19, miR-423-5p and HCN4

Our in-silicon analyses discovered two conserved 'seed sequences' of miR-423-5p on H19 (Fig.4A) and 3'UTR of HCN4 (Fig.4B), respectively. Subsequent luciferase assays showed that the luciferase activity of HL-1 cells co-transfected with miR-423-5p and wild-type H19 (Fig.4A) or HCN4 (Fig.4B) was apparently decreased, thus validating the role of H19 and HCN4 as target genes of miR-423-5p.

Molecular mechanism underlying the effect of MET in CHF treatment

The levels of H19 (Fig.4C) and HCN4 mRNA (Fig.4E)/protein (Fig.4F) were evidently decreased, along with a significantly increased level of miR-423-5p (Fig.4D), in HL-1 cells treated with 0.5 μ M or 1 μ M MET. Similarly, the transfection of HL-1 cells by H19 siRNA1 or H19 siRNA2 inhibited the expression of H19 (Fig.4G) and HCN4 mRNA (Fig.4I)/protein (Fig.4J), along with highly up-regulated expression of miR-423-5p (Fig.4H). In addition, similar results were obtained in H9C2 (Fig.5) cells treated with 0.5 μ M/1 μ M MET or H19 siRNA1/2.

In summary, the therapeutic effect of MET in CHF treatment and the synergistic effect of MET on IBD can be established by a potential molecular mechanism, in which MET exerts its inhibitory effect on H19 expression by enhancing the methylation of H19

promoter. As a result, the inhibited H19 expression up-regulates the expression of miR-423-5p and reduces the expression of HCN4, which in turn reduces heart rate and exhibits a therapeutic effect on CHF treatment.

Discussion

MET has been widely used in T2DM treatment after its approval in the U.S. and U.K. in 1995 and 1958, respectively [21]. According to the guidelines published by American Diabetes Association, MET is a first-line therapy used in the treatment of T2DM [22]. By reducing the intestinal absorption of glucose, MET can promote the uptake of peripheral glucose, enhance the sensitivity of human body to insulin, and reduce the level of insulin in fasting plasma, thus resulting in a reduced level of blood glucose without causing hypoglycemia [23]. MET is also known to activate AMPK signaling and attenuate the severity of heart failure in dogs upon the induction of rapid ventricular pacing [24]. In addition, MET was found to reduce the degree of hypertrophy and fibrosis in mice subjected to chronic stress, while preserving the LV functions and promoting the survival in mice following myocardial infarction [25, 26].

The exposure of human ovarian and endometrial cancer cells to MET can decrease the expression of H19, along with simultaneously increased methylation of H19 promoter [27]. In addition, the inhibition of H19 expression by MET can activate SAHH and not only lead to DNA methylation but also induce the methylation of proteins involved in the regulation of chromatin structures [28]. In fact, the methylation of a specific gene is not only affected by the activation of DNMTs, but also by the alterations in proteins bound to chromatin [27]. In this study, an evident reduction in the expression of H19 and HCN was observed along with a significant increase in miR-423-5p expression after the administration of MET. In addition, similar results were observed in the myocardial tissues collected from experimental rats, thus validating the positive and synergistic effects of MET and IBD in the treatment of CHF, potentially by regulating the expression of H19, miR-423-5p and HCN4.

332 Recently, the involvement of the family of HCN channels in CHF has attracted great
333 interest. HCN channels are associated with a depolarizing current known as the funny
334 current (I_f), which is responsible for the activity of cardiac pacemaker. So far, four genes,
335 including HCN1, HCN2, HCN3 and HCN4, have been identified as the genes encoding
336 HCN channels [29]. Among these four genes, HCN4 gene is most highly expressed in the
337 SA node of mammalian adults [30]. For example, HCN4 accounts for nearly 80% of all
338 HCN expression in human [30]. Consistent with such observation, HCN4 mutations
339 lacking the proper function of HCN4 have been implicated in inherited sinus bradycardia,
340 thus suggesting the important role of HCN4 in the maintenance of a normal sinus
341 rhythm [31]. While the global deletion of HCN4 in mice has been shown to induce
342 embryonic lethality, other studies on HCN4-deficient embryos demonstrated an
343 apparently decreased rate of cardiac contraction [32, 33]. It was also shown that as a
344 target gene of miR-423-5p, the inhibition of HCN4 expression can lead to increased
345 levels of both Nkx2.5 and miR-423-5p in the sinus node, which in turn cause bradycardia
346 [34]. In this study, we showed that the levels of H19 and HCN4 were decreased along
347 with an increased level of miR-423-5p after the transfection of MET or H19 siRNA1/2
348 into HL-1 and H9C2 cells.

349 The remodeling of HCN has been observed in both rodents and human athletes. In fact,
350 miR-423-5p was shown to contribute to training-induced bradycardia by inhibiting the
351 expression of HCN4 and affecting the heart rate [34]. Therefore, miR-423-5p may
352 become a therapeutic target in the treatment of sinus node dysfunction in athletes [34].
353 As a pharmaceutical recently approved to treat chronic angina pectoris, IBD is especially
354 helpful to treat patients who have a normal sinus rhythm but cannot be treated by beta
355 blockers [35]. It was also shown that IBD can regulate I_f, a mixed Na⁺-K⁺ current
356 induced by hyperpolarization and regulated by the autonomic nervous system [36].
357 Therefore, IBD can also be used to treat sinus tachycardia [37]. Moreover, IBD was
358 found to play a protective role in the management of myocardial ischemic injury [38]. In
359 fact, the beneficial value of IBD has been recognized in the treatment of chronic heart
360 failure and in the prevention of cardiovascular death [38]. In particular, IBD was shown

to reduce the heart rate in a mouse model of sinus tachycardia by upregulating the expression of HCN [39]. In contrary, it was shown that the long-term administration of IBD in infarcted rats could partially alleviate the severity of cardiac remodeling by reducing the levels of HCN4 and HCN2 expression in atrial and ventricular cardiomyocytes [40]. Moreover, coronary artery diseases and diabetes are often concomitant, while prior studies showed that the mortality in myocardial infarction patients with diabetes is higher than that in myocardial infarction patients with no diabetes [41, 42]. In addition, the prevalence of heart failure in myocardial infarction patients with diabetes is also higher in spite of optimal treatment and prompt angioplasty [43]. Interestingly, a wide range of molecular and cellular processes have been implicated in the dysregulation of cardiac functions in myocardial infarction patients with diabetes [44]. For example, it was shown that IBD can significantly restore impaired uptake-1 of NE in the sympathetic ganglion and subsequently normalize the plasma level of NE in CHF rats [45]. Similarly, the effect of IBD on enhancing the uptake-1 of NE is impaired in STZ animals [16].

Conclusion

In summary, we observed for the first that MET can improve the therapeutic effect of IBD in the treatment of concomitant CHF and DM via the H19/miR-423-5p/HCN4 axis. In fact, it has been shown that the presence of DM may reduce the therapeutic effect of IBD. Meanwhile, we found that MET may reduce the expression of H19 by enhancing the methylation status of its promoter, which subsequently increases the expression of miR-423-5p and suppresses the expression of its target, HCN4, an important player in the pathogenesis of CHF.

Conflict of interest

None

Figure legends

Fig.1

General/cardiac/echocardiographic measurements and the levels of NE/BNP-45 in the rats from the STZ, STZ+ MET, CHF, CHF+STZ, CHF+STZ+ MET, CHF+IBD, CHF+STZ+IBD, and CHF+STZ+IBD+ MET groups (* P value < 0.05, vs. control group; ** P value < 0.05, vs. CHF group; # P value < 0.05, vs CHF+STZ group).

- A. The concentration of blood glucose in the rats from different groups;
- B. Body weight of rats from different groups;
- C. Heart weight of rats from different groups;
- D. Heart weight/body weight ratio of rats from different groups;
- E. Infarct size of rats from different groups;
- F. Mean arterial pressure (MAP) of rats from different groups;
- G. Heart rate (HR) of rats from different groups;
- H. LVDD of rats from different groups;
- I. LVSD of rats from different groups;
- J. LVFS of rats from different groups;
- K. LVEDP of rats from different groups;
- L. Level of plasma NE in rats from different groups;
- M. Level of BNP-45 in rats from different groups;
- N. SR of rats from different groups;
- O. CO of rats from different groups;
- P. Clof rats from different groups.

Fig.2

Levels of H19, miR-423-5p and HCN4 mRNA/protein in rats from different groups (* P value < 0.05, vs. control group; ** P value < 0.05, vs. CHF group; # P value < 0.05, vs CHF+STZ group).

- A. Level of H19 in rats from different groups;
- B. Level of miR-423-5p in rats from different groups;
- C. Level of HCN4 mRNA in rats from different groups;
- D. Western blot analysis of HCN4 protein in rats from different groups;

416 E. Methylation status (%) of H19 in rats from different groups.

417 **Fig.3**

418 The expression of HCN4 in myocardial tissue samples of the rats from the STZ, STZ+ MET,
419 CHF, CHF+STZ, CHF+STZ+ MET, CHF+IBD, CHF+STZ+IBD, and CHF+STZ+IBD+ MET groups
420 was measured using IHC assays.

421 **Fig.4**

422 Associations among H19, miR-423-5p and HCN4 in HL-1 cells

- 423 A. In-silicon analysis for the relationship between miR-423-5p and H19, and luciferase
424 assay of HL-1 cells co-transfected with wild-type/mutant H19 and miR-423-
425 5p/control miRNA (* P value < 0.05, vs. miRNA controls);
- 426 B. In-silicon analysis for the relationship between miR-423-5p and HCN4, and luciferase
427 assay of HL-1 cells co-transfected with wild-type/mutant HCN4 and miR-423-
428 5p/control miRNA (* P value < 0.05, vs. miRNA controls);
- 429 C. Level of H19 in HL-1 cells treated with 0.5 μ M or 1 μ M MET compared with that in
430 untreated HL-1 cells (* P value < 0.05, vs. untreated cells);
- 431 D. Level of miR-423-5p in HL-1 cells treated with 0.5 μ M or 1 μ M MET compared with
432 that in untreated HL-1 cells (* P value < 0.05, vs. untreated cells);
- 433 E. Level of HCN4 mRNA in HL-1 cells treated with 0.5 μ M or 1 μ M MET compared with
434 that in untreated HL-1 cells (* P value < 0.05, vs. untreated cells);
- 435 F. Western blot analysis of HCN4 protein expressed in HL-1 cells treated with 0.5 μ M or
436 1 μ M MET compared with that in untreated HL-1 cells (* P value < 0.05, vs.
437 untreated cells);
- 438 G. Level of H19 in HL-1 cells transfected with H19 siRNA 1 or H19 siRNA2 compared
439 with that in HL-1 cells transfected with the negative control (* P value < 0.05, vs.
440 untreated cells);
- 441 H. Level of miR-423-5p in HL-1 cells transfected with H19 siRNA 1 or H19 siRNA2
442 compared with that in HL-1 cells transfected with the negative control (* P value <
443 0.05, vs. untreated cells);

- I. Level of HCN4 in HL-1 cells transfected with H19 siRNA 1 or H19 siRNA2 compared with that in HL-1 cells transfected with the negative control (* P value < 0.05, vs. untreated cells);
- J. Western blot analysis of HCN4 protein expression in HL-1 cells transfected with H19 siRNA 1 or H19 siRNA2 compared with that in HL-1 cells transfected with the negative control (* P value < 0.05, vs. untreated cells).

Fig.5

Associations among H19, miR-423-5p and HCN4 in H9C2 cells.

- A. In-silicon analysis for the relationship between miR-423-5p and H19, and luciferase assay of H9C2 cells co-transfected with wild-type/mutant H19 and miR-423-5p/control miRNA (* P value < 0.05, vs. miRNA controls);
- B. In-silicon analysis for the relationship between miR-423-5p and HCN4, and luciferase assay of H9C2 cells co-transfected with wild-type/mutant HCN4 and miR-423-5p/control miRNA (* P value < 0.05, vs. miRNA controls);
- C. Level of H19 in H9C2 cells treated with 0.5 μ M or 1 μ M MET compared with that in untreated H9C2 cells (* P value < 0.05, vs. untreated cells);
- D. Level of miR-423-5p in H9C2 cells treated with 0.5 μ M or 1 μ M MET compared with that in untreated H9C2 cells (* P value < 0.05, vs. untreated cells);
- E. Level of HCN4 mRNA in H9C2 cells treated with 0.5 μ M or 1 μ M MET compared with that in untreated H9C2 cells (* P value < 0.05, vs. untreated cells);
- F. Western blot analysis of HCN4 protein expressed in H9C2 cells treated with 0.5 μ M or 1 μ M MET compared with that in untreated H9C2 cells (* P value < 0.05, vs. untreated cells);
- G. Level of H19 in H9C2 cells transfected with H19 siRNA 1 or H19 siRNA2 compared with that in H9C2 cells transfected with the negative control (* P value < 0.05, vs. untreated cells);
- H. Level of miR-423-5p in H9C2 cells transfected with H19 siRNA 1 or H19 siRNA2 compared with that in H9C2 cells transfected with the negative control (* P value < 0.05, vs. untreated cells);

- I. Level of HCN4 in H9C2 cells transfected with H19 siRNA 1 or H19 siRNA2 compared with that in H9C2 cells transfected with the negative control (* P value < 0.05, vs. untreated cells);
- J. Western blot analysis of HCN4 protein expression in H9C2 cells transfected with H19 siRNA 1 or H19 siRNA2 compared with that in H9C2 cells transfected with the negative control (* P value < 0.05, vs. untreated cells).

References

- 1 McMurray JJ, Stewart S: Epidemiology, aetiology, and prognosis of heart failure. *Heart* 2000;83:596-602.
- 2 Mosterd A, Hoes AW: Clinical epidemiology of heart failure. *Heart* 2007;93:1137-1146.
- 3 Maggioni AP, Dahlstrom U, Filippatos G, Chioncel O, Crespo Leiro M, Drozd J, Fruhwald F, Gullestad L, Logeart D, Fabbri G, Urso R, Metra M, Parissis J, Persson H, Ponikowski P, Rauchhaus M, Voors AA, Nielsen OW, Zannad F, Tavazzi L: EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). *Eur J Heart Fail* 2013;15:808-817.
- 4 Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P: 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J* 2016;37:2129-2200.
- 5 Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Despres JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jimenez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER, 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K,

502 Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ,
503 Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Woo D, Yeh RW,
504 Turner MB: Executive Summary: Heart Disease and Stroke Statistics--2016
505 Update: A Report From the American Heart Association. *Circulation*
506 2016;133:447-454.

507 6 Biel M, Wahl-Schott C, Michalakakis S, Zong X: Hyperpolarization-activated cation
508 channels: from genes to function. *Physiol Rev* 2009;89:847-885.

509 7 Chu HY, Zhen X: Hyperpolarization-activated, cyclic nucleotide-gated (HCN)
510 channels in the regulation of midbrain dopamine systems. *Acta Pharmacol Sin*
511 2010;31:1036-1043.

512 8 Baruscotti M, Bottelli G, Milanesi R, DiFrancesco JC, DiFrancesco D: HCN-related
513 channelopathies. *Pflugers Arch* 2010;460:405-415.

514 9 Biel M, Schneider A, Wahl C: Cardiac HCN channels: structure, function, and
515 modulation. *Trends Cardiovasc Med* 2002;12:206-212.

516 10 Zwadlo C, Borlak J: Disease-associated changes in the expression of ion channels,
517 ion receptors, ion exchangers and Ca(2+)-handling proteins in heart hypertrophy.
518 *Toxicol Appl Pharmacol* 2005;207:244-256.

519 11 Zicha S, Fernandez-Velasco M, Lonardo G, L'Heureux N, Nattel S: Sinus node
520 dysfunction and hyperpolarization-activated (HCN) channel subunit remodeling
521 in a canine heart failure model. *Cardiovasc Res* 2005;66:472-481.

522 12 DiFrancesco D, Camm JA: Heart rate lowering by specific and selective I(f)
523 current inhibition with ivabradine: a new therapeutic perspective in
524 cardiovascular disease. *Drugs* 2004;64:1757-1765.

525 13 Bois P, Bescond J, Renaudon B, Lenfant J: Mode of action of bradycardic agent, S
526 16257, on ionic currents of rabbit sinoatrial node cells. *Br J Pharmacol*
527 1996;118:1051-1057.

528 14 Yue-Chun L, Teng Z, Na-Dan Z, Li-Sha G, Qin L, Xue-Qiang G, Jia-Feng L:
529 Comparison of effects of ivabradine versus carvedilol in murine model with the
530 Coxsackievirus B3-induced viral myocarditis. *PLoS One* 2012;7:e39394.

531 15 Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G,
532 Tavazzi L: Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised
533 placebo-controlled study. *Lancet* 2010;376:875-885.

534 16 Cao X, Sun Z, Zhang B, Li X, Xia H: The Effects of Ivabradine on Cardiac Function
535 after Myocardial Infarction are Weaker in Diabetic Rats. *Cell Physiol Biochem*
536 2016;39:2055-2064.

537 17 Wu T, Qu L, He G, Tian L, Li L, Zhou H, Jin Q, Ren J, Wang Y, Wang J, Kan X, Liu M,
538 Shen J, Guo M, Sun Y: Regulation of laryngeal squamous cell cancer progression
539 by the lncRNA H19/miR-148a-3p/DNMT1 axis. *Oncotarget* 2016;7:11553-11566.

540 18 Srivastava M, Hsieh S, Grinberg A, Williams-Simons L, Huang SP, Pfeifer K: H19
541 and Igf2 monoallelic expression is regulated in two distinct ways by a shared cis
542 acting regulatory region upstream of H19. *Genes Dev* 2000;14:1186-1195.

543 19 Kawakami T, Zhang C, Okada Y, Okamoto K: Erasure of methylation imprint at
544 the promoter and CTCF-binding site upstream of h19 in human testicular germ cell
545 tumors of adolescents indicate their fetal germ cell origin. *Oncogene* 2006;
546 25:3225-3236.

547 20 Yan L, Zhou J, Gao Y, Ghazal S, Lu L, Bellone S, Yang Y, Liu N, Zhao X, Santin AD,
548 Taylor H, Huang Y: Regulation of tumor cell migration and invasion by the
549 H19/let-7 axis is antagonized by metformin-induced DNA methylation. *Oncogene*
550 2015;34:3076-3084.

551 21 Scarpello JH, Howlett HC: Metformin therapy and clinical uses. *Diab Vasc Dis Res*
552 2008;5:157-167.

553 22 Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters
554 AL, Tsapas A, Wender R, Matthews DR: Management of hyperglycaemia in type 2
555 diabetes: a patient-centered approach. Position statement of the American
556 Diabetes Association (ADA) and the European Association for the Study of
557 Diabetes (EASD). *Diabetologia* 2012;55:1577-1596.

- 558 23 Grzybowska M, Bober J, Olszewska M: [Metformin - mechanisms of action and
559 use for the treatment of type 2 diabetes mellitus]. Postepy Hig Med Dosw
560 (Online) 2011;65:277-285.
- 561 24 Sasaki H, Asanuma H, Fujita M, Takahama H, Wakeno M, Ito S, Ogai A, Asakura M,
562 Kim J, Minamino T, Takashima S, Sanada S, Sugimachi M, Komamura K,
563 Mochizuki N, Kitakaze M: Metformin prevents progression of heart failure in
564 dogs: role of AMP-activated protein kinase. Circulation 2009;119:2568-2577.
- 565 25 Xiao H, Ma X, Feng W, Fu Y, Lu Z, Xu M, Shen Q, Zhu Y, Zhang Y: Metformin
566 attenuates cardiac fibrosis by inhibiting the TGFbeta1-Smad3 signalling pathway.
567 Cardiovasc Res 2010;87:504-513.
- 568 26 Gundewar S, Calvert JW, Jha S, Toedt-Pingel I, Ji SY, Nunez D, Ramachandran A,
569 Anaya-Cisneros M, Tian R, Lefer DJ: Activation of AMP-activated protein kinase
570 by metformin improves left ventricular function and survival in heart failure. Circ
571 Res 2009;104:403-411.
- 572 27 Jin B, Ernst J, Tiedemann RL, Xu H, Sureshchandra S, Kellis M, Dalton S, Liu C, Choi
573 JH, Robertson KD: Linking DNA methyltransferases to epigenetic marks and
574 nucleosome structure genome-wide in human tumor cells. Cell Rep 2012;2:1411-
575 1424.
- 576 28 Zhong T, Men Y, Lu L, Geng T, Zhou J, Mitsuhashi A, Shozu M, Maihle NJ,
577 Carmichael GG, Taylor HS, Huang Y: Metformin alters DNA methylation genome-
578 wide via the H19/SAHH axis. Oncogene 2017;36:2345-2354.
- 579 29 Noble D, Noble PJ: Late sodium current in the pathophysiology of cardiovascular
580 disease: consequences of sodium-calcium overload. Heart 2006;92 Suppl 4:iv1-
581 iv5.
- 582 30 Hale SL, Kloner RA: Ranolazine treatment for myocardial infarction? Effects on
583 the development of necrosis, left ventricular function and arrhythmias in
584 experimental models. Cardiovasc Drugs Ther 2014;28:469-475.
- 585 31 Mourouzis I, Mantzouratou P, Galanopoulos G, Kostakou E, Dhalla AK,
586 Belardinelli L, Pantos C: The beneficial effects of ranolazine on cardiac function

587 after myocardial infarction are greater in diabetic than in nondiabetic rats. J
588 Cardiovasc Pharmacol Ther 2014;19:457-469.

589 32 Sossalla S, Maier LS: Role of ranolazine in angina, heart failure, arrhythmias, and
590 diabetes. Pharmacol Ther 2012;133:311-323.

591 33 Brede M, Wiesmann F, Jahns R, Hadamek K, Arnolt C, Neubauer S, Lohse MJ,
592 Hein L: Feedback inhibition of catecholamine release by two different alpha2-
593 adrenoceptor subtypes prevents progression of heart failure. Circulation
594 2002;106:2491-2496.

595 34 D'Souza A, Pearman CM, Wang Y, Nakao S, Logantha S, Cox C, Bennett H, Zhang Y,
596 Johnsen AB, Linscheid N, Poulsen PC, Elliott J, Coulson J, McPhee J, Robertson A,
597 da Costa Martins PA, Kitmitto A, Wisloff U, Cartwright EJ, Monfredi O, Lundby A,
598 Dobrzynski H, Oceandy D, Morris GM, Boyett MR: Targeting miR-423-5p
599 Reverses Exercise Training-Induced HCN4 Channel Remodeling and Sinus
600 Bradycardia. Circ Res 2017;121:1058-1068.

601 35 Oeing CU, Tschope C, Pieske B: [The new ESC Guidelines for acute and chronic
602 heart failure 2016]. Herz 2016;41:655-663.

603 36 Sulfi S, Timmis AD: Ivabradine -- the first selective sinus node I(f) channel
604 inhibitor in the treatment of stable angina. Int J Clin Pract 2006;60:222-228.

605 37 Yusuf S, Camm AJ: Sinus tachyarrhythmias and the specific bradycardic agents: a
606 marriage made in heaven? J Cardiovasc Pharmacol Ther 2003;8:89-105.

607 38 Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R: Ivabradine in stable
608 coronary artery disease without clinical heart failure. N Engl J Med
609 2014;371:1091-1099.

610 39 Leoni AL, Marionneau C, Demolombe S, Le Bouter S, Mangoni ME, Escande D,
611 Charpentier F: Chronic heart rate reduction remodels ion channel transcripts in
612 the mouse sinoatrial node but not in the ventricle. Physiol Genomics 2005;24:4-
613 12.

614 40 Suffredini S, Stillitano F, Comini L, Bouly M, Brogioni S, Ceconi C, Ferrari R,
615 Mugelli A, Cerbai E: Long-term treatment with ivabradine in post-myocardial

616 infarcted rats counteracts f-channel overexpression. Br J Pharmacol
617 2012;165:1457-1466.

618 41 Chiha M, Njeim M, Chedrawy EG: Diabetes and coronary heart disease: a risk
619 factor for the global epidemic. Int J Hypertens 2012;2012:697240.

620 42 Donahoe SM, Stewart GC, McCabe CH, Mohanavelu S, Murphy SA, Cannon CP,
621 Antman EM: Diabetes and mortality following acute coronary syndromes. JAMA
622 2007;298:765-775.

623 43 Carrabba N, Valenti R, Parodi G, Santoro GM, Antoniucci D: Left ventricular
624 remodeling and heart failure in diabetic patients treated with primary
625 angioplasty for acute myocardial infarction. Circulation 2004;110:1974-1979.

626 44 Shi YQ, Yan M, Liu LR, Zhang X, Wang X, Geng HZ, Zhao X, Li BX: High Glucose
627 Represses hERG K⁺ Channel Expression through Trafficking Inhibition. Cell
628 Physiol Biochem 2015;37:284-296.

629 45 Davis D, Sinoway LI, Robison J, Minotti JR, Day FP, Baily R, Zelis R:
630 Norepinephrine kinetics during orthostatic stress in congestive heart failure. Circ
631 Res 1987;61:187-90.

632

633

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5